TDF and Entekavir - Hepatitis B Reactivation

Efficacy of TDF and Entekavir Prophylaxis at Hepatitis B Reactivation: Multi Center Retrospective Study

NCT06049602•Viral Hepatitis Society

Summary

This is a non-interventional retrospective multi-center study for the patients received Entekavir or TDF for Hepatitis B prophylaxis.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients used entekavir or TDF for Hepatitis B prophylaxis

Exclusion Criteria

•Patients lower then 18 years old.

Locations (1)

Cerrahpasa Medical Faculty

Istanbul, Turkey (Türkiye)

Key Dates

Start Date

January 15, 2023

Primary Completion Date

December 31, 2023

Completion Date

December 31, 2023

Last Updated

September 22, 2023

Enrollment

10,000

ESTIMATED participants

Conditions

Hepatitis B Reactivation

Contacts

Fehmi Tabak, Prof

CONTACT

+905322763788 fehmitabak@yahoo.com

Ilker Kurkcu

CONTACT

+905326354515 ilker.kurkcu@sentez-cro.com

TAF to Prevent HBV Reactivation in Cancer Patients

NCT04619082

Hepatitis B Reactivation

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 22, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions